The authors correlated these results with an analysis of pathway activation in breast cancer patients who had progressed on letrozole, finding an upregulation of PI3KA, pAkt and p-mTOR after three months on treatment in comparison to the patients' pre-treatment baseline. This evidence concerns the gene MTOR and breast carcinoma.